{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-043915","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.151096+00:00","generated_at":"2026-05-30T03:54:02.233128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cingulate posts narrower Q3 loss, cash jumps to $10M as it advances ADHD drug toward mid-2025 NDA","bullets":["Net loss $3.2M vs $6.0M in Q3 2023; R&D expenses fell $2.5M to $1.4M.","Cash and equivalents $10M at Sep 30, 2024, up from $52K at Dec 31, 2023.","Working capital $9.8M, an increase of $19.5M from negative $9.6M at year-end 2023.","Raised ~$12.5M in Q3; cash runway extended into Q3 2025.","Commenced final FDA food-effect study for CTx-1301; data readout by end of 2024; NDA submission targeted mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-043915","json":"https://secwatch.observer/filing/0001493152-24-043915.json","markdown":"https://secwatch.observer/filing/0001493152-24-043915.md","text":"https://secwatch.observer/filing/0001493152-24-043915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224043915/0001493152-24-043915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224043915/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:54:02.233128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}